Feed / RCUS

Arcus Biosciences, Inc.

RCUS

Healthcare · 30.37 +2.9% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Arcus Biosciences, Inc.'s move is being confirmed by its market group.

RCUS accounts for 9.8% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#4 of 12 by movement share
Group movement share9.8%Absolute path energy—not portfolio weight
Relative path+2.22%aligned
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

ALMS, GPCR, PRAX moved materially before RCUS. RCUS crossed its material path threshold at 15:05 ET, 1395 minutes after the first measured mover. MAZE, TYRA followed.

EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 7 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind RCUS

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

GILDGilead Sciences, Inc.partnerMay 5, 2026 ▾

“TIGIT Program (domvanalimab) • In December 2025, we announced the discontinuation of the Phase 3 STAR-221 study, conducted in partnership with Gilead and Taiho, evaluating a domvanalimab-based combination in upper gastrointestinal cancers due to futility: ◦ T…”

AZNAstraZeneca PLCpartnerOct 28, 2025 ▾

“In October 2025, we announced eVOLVE-RCC02, a Phase 1b/3 study sponsored and operationalized by AstraZeneca, evaluating casdatifan plus volrustomig, AstraZeneca's investigational anti-PD-1/CTLA-4 bispecific antibody, in first-line, metastatic clear cell renal…”

Depended on by

GILDGilead Sciences, Inc.investeeMay 7, 2026 ▾

“For equity investments in our strategic partners, such as in connection with our collaborations with Arcus Biosciences, Inc.”

Filing peers

ERNAASIXSOC

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 6 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

RCUS is currently a Follower in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.